Exact Sciences
Madison, Wisconsin

Overall Rank: 32
Category: Biotechnology
Category Rank: 14


  • Top HealthTech Company of 2023


Exact Sciences Corp. is a molecular diagnostics company specializing in the detection of early stage cancers. The company’s initial focus was on the early detection and prevention of colorectal cancer, in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to encompass other screening and precision oncological tests for other types of cancer.

Visit: www.exactsciences.com

Key Products

Cologuard®, the first and only noninvasive stool DNA colorectal cancer screening test.

Oncotype DX® Pan-Cancer Tissue test to help guide treatment for patients with advanced cancer.

Oncoguard™ Liver, a test to help identify hepatocellular carcinoma (HCC) for adults suffering from liver cirrhosis or chronic hepatitis B.

Riskguard™ Hereditary Cancer Test is a 32-gene Next-Gen Sequencing test for those who want to understand their risk of developing inherited forms of cancer, why cancer may be common in their family, and their screening options.

Key Executives

Kevin Conroy, Chairman of the Board and CEO

Kevin Conroy became CEO of Exact Sciences in 2009 and Chairman in 2014, transforming the organization into one of the world’s premier cancer diagnostics companies with more than 6,500 employees.

Jeff Elliott, Executive Vice President, Chief Financial Officer and Chief Operating Officer

Jeff Elliott has served as Exact Sciences Executive Vice President and Chief Operating Officer since April 2021, and Chief Financial Officer since November 2016.

Everett Cunningham, Chief Commercial Officer

Everett Cunningham joined as the Chief Commercial Officer in 2021. Mr. Cunningham brings over 25 years of progressive responsibility in pharmaceuticals and medical services and a commitment to leadership excellence.

Jorge Garces, Chief Science Officer

Jorge Garces has served as Chief Science Officer since April 2021. He served as Vice President, Minimal Residual Disease (MRD) and Therapy Selection from February 2021 to April 2021. Mr. Garces brings decades of experience in diagnostics including a focus on the development, clinical trials, and commercialization of liquid biopsy tests in the field of oncology.

Ana Hooker, Chief Laboratory Officer

Ana Hooker has served as Chief Laboratory Officer since 2022 and previously served as Senior Vice President, Operations since 2013. Prior to joining Exact Sciences, Ms. Hooker was at ARUP Laboratories for 15 years, serving in roles including Senior Vice President, Division Manager for anatomic pathology, oncology, and genetics, Vice President Division Manager for genetics, and Group Manager for oncology and genetics.

Sri Kalluri, Chief Information Officer

Sri Kalluri joined as the Chief Information Officer in May 2022. Mr. Kalluri brings over 20 years of experience and is responsible for IT operations, leveraging cutting-edge technology to unlock breakthrough levels of corporate revenue growth, productivity, and market expansion, and defining, executing and managing a successful customer experience.

Scott Coward, Chief Legal Officer

Scott Coward has served as the Chief Legal Officer since 2022, and previously served in increasing roles of responsibility, including as Executive Vice President, General Counsel, Chief Administrative Officer and Secretary; and Chief Administrative Officer since July 2018.

Paul Limburg, Chief Medical Officer, Screening

Paul Limburg has served as the Chief Medical Officer, Screening since 2019. Dr. Limburg holds the academic rank of Professor of Medicine in the Mayo Clinic College of Medicine.

Customer insights

“All of this has allowed me to gain a unique perspective from being a breast cancer surgeon and breast cancer patient. Now I know what it’s like to face cancer. I have walked in my patients’ shoes.” – Dr. Deepa Halaharvi, breast cancer survivor

Company insights

“Exact sciences is built on the core values of innovation, integrity, quality, teamwork, and accountability. These guide our commitments to fighting cancer, building brighter communities, and creating a more sustainable world.” – Kevin Conroy, Chairman & CEO